From CEO-itis to FDA-itis, the path of a biotech company is never dull.
Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting turns. Some experiences, like witnessing one of your portfolio companies transform the standard of care for patients,
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed